| Literature DB >> 35802496 |
Franziska R Traube1, Marcel Stern2, Annika J Tölke1, Martina Rudelius3, Ernesto Mejías-Pérez2, Nada Raddaoui1, Beate M Kümmerer4,5, Céline Douat6, Filipp Streshnev1, Manuel Albanese2, Paul R Wratil2, Yasmin V Gärtner1, Milda Nainytė1, Grazia Giorgio7, Stylianos Michalakis7, Sabine Schneider1, Hendrik Streeck4, Markus Müller1, Oliver T Keppler2, Thomas Carell1.
Abstract
The emergence of more transmissible or aggressive variants of SARS-CoV-2 requires the development of antiviral medication that is quickly adjustable to evolving viral escape mutations. Here we report the synthesis of chemically stabilized small interfering RNA (siRNA) against SARS-CoV-2. The siRNA can be further modified with receptor ligands such as peptides using CuI -catalysed click-chemistry. We demonstrate that optimized siRNAs can reduce viral loads and virus-induced cytotoxicity by up to five orders of magnitude in cell lines challenged with SARS-CoV-2. Furthermore, we show that an ACE2-binding peptide-conjugated siRNA is able to reduce virus replication and virus-induced apoptosis in 3D mucociliary lung microtissues. The adjustment of the siRNA sequence allows a rapid adaptation of their antiviral activity against different variants of concern. The ability to conjugate the siRNA via click-chemistry to receptor ligands facilitates the construction of targeted siRNAs for a flexible antiviral defence strategy.Entities:
Keywords: Corona pandemic; SARS-CoV-2; antiviral compounds; peptide RNA conjugates; siRNA
Mesh:
Substances:
Year: 2022 PMID: 35802496 PMCID: PMC9350007 DOI: 10.1002/anie.202204556
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 16.823